Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial

Haematologica

Volumn 87, Issue 2, 2002, Pages 154-166

  Ribera, Josep Maria ^a   Ortega, Juan José ^a   Oriol, Albert ^a   Granada, Isabel ^a   Hernández Rivas, Jesús Maria ^a   Parody, Ricardo ^a   Bethencourt, Concepción ^a   Rivas, Concepción ^a   Bastida, Pilar ^a   Del Potro, Eloy ^a   González Valentín, Maria Elvira ^a   Moreno, María José ^a   Besalduch, Joan ^a   Fernández Calvo, Javier ^a   Tormo, Mar ^a   Arias, Jesús ^a   Molinés, Antonio ^a   Sanz, Miguel Angel ^a   Maldonado, Juan ^a   Millá, Fuensanta ^a   Feliu, Evarist ^a   San Miguel, Jesús Fernando ^a   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Acute lymphoblastic leukemia; Adults; Children; Cytogenetics; High risk; T(9; 22)

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ARTICLE; BLAST CELL; BLOOD SMEAR; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INFANT; KARYOTYPING; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LIFE TABLES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHILADELPHIA CHROMOSOME; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 0036175253     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia
2. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: Results of MRC UKALL X
3. New approaches in acute lymphoblastic leukemia in adults: Were do we go?
4. Acute lymphoblastic leukemia
5. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia
6. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study
7. The GIMEMA ALL 0183 trial: Analysis of 10-year follow-up
8. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL)
9. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone
10. Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X
11. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12,000 randomised children
12. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA
13. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience
14. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: A Nordic series comparing two treatment periods
15. Proposals for the classification of acute leukaemias
16. The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations
17. Treatment of high-risk acute lymphoblastic leukemia. Preliminary results of the protocol PETHEMA ALL-93
18. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89)
19. Nonparametric estimation from incomplete observations
20. Conservatism of the approximation σ (0-E)2-E in the logrank test for survival data or tumor incidence data
21. Regression models and life tables
22. Nonparametric confidence limits for survival probabilities and median survival time
23. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation
24. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy
25. Consolidation treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation
26. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87
27. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission
28. Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: Results from Medical Research Council UKALL X and XI
29. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group
30. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR): Early results from the International ALL trial (MRC UKALL XII/ECOG2993)
31. Bone marrow transplantation for acute lymphocytic leukaemia
32. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome
33. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases
34. Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
35. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes)
36. Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
37. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the children's cancer group
38. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
39. International childhood acute lymphoblastic leukemia workshop: Sausalito, CA, 30 November-1 December 2000
40. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: A report from the Children's Cancer Group
41. +) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome
42. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
43. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
44. Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukemia: A prospective analysis of 437 cases and its application for designing induction chemotherapy trials
45. FLAG-idarubicin and allogeneic stem-cell transplantation for Ph-positive ALL beyond first remission
46. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia
47. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
48. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation
49. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with bone marrow transplantation in first complete remission
50. A phase II study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome-positive acute leukemias
51. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
52. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia
53. Secondary chromosomal aberrations in 255 childhood cases of Ph-positive acute lymphoblastic leukemia (ALL)
54. Cytogenetic studies of infant acute lymphoblastic leukemia: Poor prognosis of infants with t(4;11) - A report of the Children's Cancer Group
55. Hematologic malignancies with t(4;11)(q21;q23). A cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases
56. Hematologic malignancies with a deletion of 11q23: Cytogenetic and clinical aspects
57. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11) (q21;q23) chromosomal translocation
58. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia
59. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
60. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
61. Deletions and losses in chromosomes 5 or 7 in adult acute lymphoblastic leukemia: Incidence, associations and implications